Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium

[1]  T. Efferth,et al.  Chemotherapy-induced resistance by ATP-binding cassette transporter genes. , 2007, Biochimica et biophysica acta.

[2]  Anil K Sood,et al.  Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. , 2007, Cancer research.

[3]  Bernd R Binder,et al.  uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s view , 2007, Thrombosis and Haemostasis.

[4]  M. Horsman,et al.  Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. , 2006, Cancer research.

[5]  C. Ricciardelli,et al.  Extracellular matrix of ovarian tumors. , 2006, Seminars in reproductive medicine.

[6]  S. Zucker,et al.  The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. , 2006, Cancer research.

[7]  P. Quax,et al.  Pericellular proteases in angiogenesis and vasculogenesis. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[9]  Roy Bicknell,et al.  Tumour vascular targeting , 2005, Nature Reviews Cancer.

[10]  Dario Neri,et al.  In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature , 2005, Nature Methods.

[11]  Dean Y. Li,et al.  The axonal attractant Netrin-1 is an angiogenic factor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Tsao,et al.  Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers , 2004, Oncogene.

[13]  K. Klinger,et al.  Alterations in Vascular Gene Expression in Invasive Breast Carcinoma , 2004, Cancer Research.

[14]  Viatcheslav R Akmaev,et al.  Vascular gene expression in nonneoplastic and malignant brain. , 2004, The American journal of pathology.

[15]  Yan Li,et al.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy , 2004, Nature.

[16]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[17]  D. Neri,et al.  Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study , 2004, Proteomics.

[18]  Edison T Liu,et al.  Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. , 2004, Molecular cancer therapeutics.

[19]  M. Sahin-Tóth,et al.  Human Mesotrypsin Is a Unique Digestive Protease Specialized for the Degradation of Trypsin Inhibitors* , 2003, Journal of Biological Chemistry.

[20]  Erkki Ruoslahti,et al.  Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. , 2003, Cancer cell.

[21]  David Botstein,et al.  Endothelial cell diversity revealed by global expression profiling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Labianca,et al.  Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. , 2003, European journal of cancer.

[23]  Peter Carmeliet,et al.  Blood vessels and nerves: common signals, pathways and diseases , 2003, Nature Reviews Genetics.

[24]  D. Walsh,et al.  Enhancement of Angiogenesis by Endogenous Substance P Release and Neurokinin-1 Receptors During Neurogenic Inflammation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[25]  George Matcuk,et al.  Identification of endothelial cell genes by combined database mining and microarray analysis. , 2003, Physiological genomics.

[26]  S. Larson,et al.  A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  G. Yehia,et al.  Hematopoietic growth factor inducible neurokinin-1 type: a transmembrane protein that is similar to neurokinin 1 interacts with substance P , 2003, Regulatory Peptides.

[28]  R. Weichselbaum,et al.  Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells , 2003, Journal of Cell Science.

[29]  A. Nakao,et al.  Smad7 Suppresses the Inhibitory Effect of TGF-&bgr;2 on Corneal Endothelial Cell Proliferation and Accelerates Corneal Endothelial Wound Closure In Vitro , 2003, Cornea.

[30]  Koichi Hattori,et al.  Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases , 2003, Current opinion in hematology.

[31]  R. Béliveau,et al.  Differences in multidrug resistance phenotype and matrix metalloproteinases activity between endothelial cells from normal brain and glioma , 2003, Journal of neurochemistry.

[32]  I. Herman,et al.  Mechanisms of normal and tumor-derived angiogenesis. , 2002, American journal of physiology. Cell physiology.

[33]  D J Mooney,et al.  Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. , 2001, Cancer research.

[34]  A. Chédotal,et al.  Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine A2b receptor , 2000, Nature.

[35]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[36]  W. Stetler-Stevenson,et al.  Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells. , 2000, Experimental cell research.

[37]  J. Remacle,et al.  Identification of hypoxia-responsive messengers expressed in human microvascular endothelial cells using differential display RT-PCR. , 2000, European journal of biochemistry.

[38]  F. Peale,et al.  Gene expression profiling in an in vitro model of angiogenesis. , 2000, The American journal of pathology.

[39]  A. Kim,et al.  Identification of tumor angiogenesis-related genes by subtractive hybridization. , 2000, Microvascular research.

[40]  C. López-Otín,et al.  ADAM 23/MDC3, a Human Disintegrin That Promotes Cell Adhesion via Interaction with the αvβ3 Integrin through an RGD-independent Mechanism , 2000 .

[41]  Y. Ohya,et al.  Metalloproteinase-like, disintegrin-like, cysteine-rich proteins MDC2 and MDC3: novel human cellular disintegrins highly expressed in the brain. , 1998, The Biochemical journal.

[42]  G. Groenewegen,et al.  CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells. , 1997, Blood.

[43]  C. Garlanda,et al.  Heterogeneity of endothelial cells. Specific markers. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[44]  CeciliaGarlanda,et al.  Heterogeneity of Endothelial Cells , 1997 .

[45]  M. Kito,et al.  Identification and Expression of the cDNA-encoding Human Mesotrypsin(ogen), an Isoform of Trypsin with Inhibitor Resistance* , 1997, The Journal of Biological Chemistry.

[46]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[47]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[48]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[49]  J. Polak,et al.  Microvascular substance P binding to normal and inflamed rat and human synovium. , 1993, The Journal of pharmacology and experimental therapeutics.

[50]  C. Maggi,et al.  NK-1, but not NK-2, tachykinin receptors mediate plasma extravasation induced by antidromic C-fiber stimulation in rat hindpaw: Demonstrated with the NK-1 antagonist CP-96,345 and the NK-2 antagonist Men 10207 , 1992, Neuroscience Letters.

[51]  C. Maggi,et al.  Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. , 1990, Microvascular research.

[52]  L. Old,et al.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[53]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[54]  石渡 俊次.  Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer , 2005 .

[55]  Kazuhisa Takahashi,et al.  Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. , 2005, Anticancer research.

[56]  F. Landoni,et al.  Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells , 2004, Clinical & Experimental Metastasis.

[57]  Michael H. Gorn,et al.  Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays , 2004, Angiogenesis.

[58]  David Botstein,et al.  SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data , 2003, Nucleic Acids Res..

[59]  C. López-Otín,et al.  ADAM 23/MDC3, a human disintegrin that promotes cell adhesion via interaction with the alphavbeta3 integrin through an RGD-independent mechanism. , 2000, Molecular biology of the cell.

[60]  L. Zardi,et al.  Isolation and characterization of human tumor-derived capillary endothelial cells: role of oncofetal fibronectin. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[61]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.